Recruiting

Biomarkers for Endometriosis

Sponsor:

Trio Fertility

Code:

NCT07713797

Conditions

Endometriosis

Eligibility Criteria

Sex: Female

Age: 18 - 45

Healthy Volunteers: Accepted

Interventions

SNCG Protein

BCL-6 Protein

Study Details

Brief summary:

Endometriosis is a condition in which tissue similar to the lining of the uterus grows outside the uterus, often causing pain and infertility. Currently, endometriosis can only be definitively diagnosed through invasive procedures like laparoscopy and biopsy.

The purpose of this study is to investigate whether the proteins Synuclein Gamma (SNCG) and B-Cell Lymphoma 6 (BCL6), measurable in blood and menstrual fluid, can serve as non-invasive biomarkers to diagnose or monitor endometriosis.

Conditions

Endometriosis

Study ID

NCT07713797

Start date

Jan 16, 2026

Status verified date

Jul, 2026

Completion date

Sep 1, 2027

Anticipated

Primary completion date

Jan 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 45

Healthy Volunteers: Accepted

Inclusion Criteria for Endometriosis Group:

  • Women of reproductive age group (18Y-45Y).
  • Women with active endometriosis diagnosed by ultrasound/MRI/laparoscopy.

Exclusion Criteria for Endometriosis Group:

  • Women <18Y and >45Y.
  • Women with endometriosis during stimulation with gonadotropins.
  • Current or prior history of uterine, ovarian, colon, pancreatic, breast or any other type of cancer.
  • Any prior history of chronic illness.
  • Pregnant women.

Inclusion Criteria for Control Group:

  • Women of reproductive age group (18Y-45Y).
  • Women without endometriosis and any other gynaecological problem.

Exclusion Criteria for Endometriosis Group:

  • Women <18Y and >45Y
  • Prior history of any disease including cancer or chronic illness.
  • Pregnant women.

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Arms

Endometriosis Group

Patients who have been diagnosed with Endometriosis

Control Group

Patients who have not been diagnosed with Endometriosis

Interventions

SNCG Protein

Synuclein gamma (SNCG), a member of the synuclein family of neuronal proteins, is involved in cellular proliferation by interacting with the mitotic checkpoint kinase BubR1, and inhibiting its regulatory role on cellular proliferation. During the last decade, several studies have demonstrated that SNCG is correlated with poor outcome of breast cancer, ovarian cancer, colon cancer and pancreatic cancer. Interestingly, SNCG has previously been shown to have elevated expression ranging from 5- to 53-fold in ovarian endothelial cells of endometriosis lesions compared with eutopic endometrium from the same individual.

BCL-6 Protein

B-Cell Lymphoma 6 (BCL6) protein is encoded by the BCL6 oncogene and is a zinc finger transcription factor that regulates the transcription of signal transducer and activators of transcription (STAT)-dependent IL-4 responses of B-cells. Previously, BCL6 was shown to express in the endometrial epithelial cells and B-cells in lymph node germinal centers. In addition, over-expression of BCL6 has been reported in endometrial biopsies and has been linked to the progesterone resistance and pathogenesis of endometriosis

Primary outcome measure

  • Synuclein Gamma (SNCG) and B-cell Lymphoma 6 (BCL-6) Levels [ Time Frame: Baseline for control participants and baseline and approximately 3 months after treatment for participants with endometriosis ]

Central Contacts and Locations

Central contacts

Yasaman Sadeghi, M.Sc.

4165060804yasamans@triofertility.com

Locations

Trio Fertility

Recruiting

Toronto, Ontario, Canada, M5G 2K4

Contacts

Yasaman Sadeghi

4165060804yasamans@triofertility.com

More Information

Sponsor

Trio Fertility

Last update posted

Aug 3, 2026

Last verified

Jul, 2026

Keywords

  • endometriosis
  • biomarkers
  • BCL6
  • SNCG

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-15. This information was provided to ClinicalTrials.gov by Trio Fertility on 2026-08-03.